Gemma Echarri

Gemma Echarri


Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2016 in British Journal of Anaesthesia
Verified
Journal Article
Closed access
Marc VivesMarc Vives
Marc Vives
RCR Callejas
R Callejas
PDP Duque
P Duque
GEGemma Echarri
Gemma Echarri
DWD.N. Wijeysundera
D.N. Wijeysundera
PMP Monedero
P Monedero
Recent trials have shown hydroxyethyl starch (HES) solutions increase the risk of acute kidney injury (AKI) in critically ill patients. It is uncertain whether these adverse effects also affect surgical patients. We sought to determine the renal safety of modern tetrastarch (6% HES 130/0.4) use in cardiac surgical patients. In this multicentre prospective cohort study, 1058 consecutive patients who underwent cardiac surgery from 15th September 2012 to 15th December 2012 were recruited in 23 Spanish hospitals. We identified 350 patients (33%) administered 6% HES 130/0.4 intraoperatively and postoperatively, and 377 (36%) experienced postoperative AKI (AKI Network criteria). In-hospital death occurred in 45 (4.2%) patients. Patients in the non-HES group had higher Euroscore and more comorbidities including unstable angina, preoperative cardiogenic shock, preoperative intra-aortic balloon pump use, peripheral arterial disease, and pulmonary hypertension. The non-HES group received more intraoperative vasopressors and had longer cardiopulmonary bypass times. After multivariable risk-adjustment, 6% HES 130/0.4 use was not associated with significantly increased risks of AKI (adjusted odds ratio 1.01, 95% CI 0.71-1.46, P=0.91). These results were confirmed by propensity score-matched pairs analyses. The intraoperative and postoperative use of modern hydroxyethyl starch 6% HES 130/0.4 was not associated with increased risks of AKI and dialysis after cardiac surgery in our multicentre cohort.

1 November 2009 in European Journal of Anaesthesiology
Verified
Journal Article
Closed access
CMCissé-Luc Mbongo
Cissé-Luc Mbongo
PMPablo Monedero
Pablo Monedero
Francisco Guillen-GrimaFrancisco Guillen-Grima
Francisco Guillen-Grima
MYMaria J Yepes
Maria J Yepes
MVMarc Vives
Marc Vives
GEGemma Echarri
Gemma Echarri
Simplified Acute Physiology Score (SAPS3) has not been validated in Southern European countries. The purpose of this study was to validate the ability of SAPS3 to predict hospital mortality in adult patients in an interdisciplinary intensive care unit in Southern Europe, compared with Acute Physiology and Chronic Health Evaluation (APACHE) II and Sequential Organ Failure Assessment (SOFA). This is a cohort study of 864 patients with a prospective collection of SAPS3 and SOFA variables and retrospective analysis of APACHE II in a mixed intensive care unit at a teaching hospital in Spain throughout 2006. The performance of the systems was determined by examining their discrimination and calibration. The discrimination of SAPS3 was excellent, with an area under the receiver operating characteristic curve of 0.916, similar to APACHE II (area under the receiver operating characteristic curve = 0.893) or SOFA (area under the receiver operating characteristic curve = 0.846). The calibration was good for SAPS3 but insufficient for APACHE II. Hospital death rates were lower than those that were predicted by the models. Our data demonstrate a better calibration of SAPS3 than APACHE II. Calibration was sufficient only for SAPS3. Hospital mortality was lower than predicted by both models. The discrimination of SAPS3 is excellent, and, when it is customized for Southern Europe, SAPS3 accurately predicts mortality risk in our adult mixed-case ICU.

22 February 2017 in PLOS ONE
Verified
Journal Article
Open access
PDF file
PDPaula Duque-Sosa
Paula Duque-Sosa
DMDiego Martínez
Diego Martínez
GEGemma Echarri
Gemma Echarri
RCRaquel Callejas
Raquel Callejas
MIMaría Josefa Iribarren
María Josefa Iribarren
S(Spanish group of renal dysfunction in cardiac surgery (GEDRCC-2)
Spanish group of renal dysfunction in cardiac surgery (GEDRCC-2)
Perioperative anemia is an important risk factor for cardiac surgery-associated acute kidney injury (CSA-AKI). Nonetheless, the severity of the anemia and the time in the perioperative period in which the hemoglobin level should be considered as a risk factor is conflicting. The present study introduces the concept of perioperative hemoglobin area under the curve (pHb-AUC) as a surrogate marker of the evolution of perioperative hemoglobin concentration. Through a retrospective analysis of prospectively collected data, we assessed this new variable as a risk factor for the development of acute kidney injury after cardiac surgery in 966 adult patients who underwent cardiac surgery with cardiopulmonary bypass, at twenty-three academic hospitals in Spain. Exclusion criteria were patients on renal replacement therapy, who needed a reoperation because of bleeding and/or with missing perioperative hemoglobin or creatinine values. Using a multivariate regression analysis, we found that a pHb-AUC <19 g/dL was an independent risk factor for CSA-AKI even after adjustment for intraoperative red blood cell transfusion (OR 1.41, p <0.05). It was also associated with mortality (OR 2.48, p <0.01) and prolonged hospital length of stay (4.67 ± 0.99 days, p <0.001)

Verified
Journal Article
Open access
PDF file
IRIñigo Rubio-Baines
Iñigo Rubio-Baines
LCLuigi Camporota
Luigi Camporota
DGDuilio González-Delgado
Duilio González-Delgado
GEGemma Echarri
Gemma Echarri
MSMaria Carmen Sala-Trull
Maria Carmen Sala-Trull
Marc VivesMarc Vives
Marc Vives
Background: Human serum albumin (HSA), the most abundant plasma protein, is essential for oncotic pressure, endothelial protection, drug binding, and immune modulation. Despite its widespread clinical use since the 1940s, its therapeutic benefit in critically ill patients remains debated. This narrative review summarizes current evidence on HSA use in common intensive care scenarios. Clinical Applications: In hepatorenal syndrome (HRS), albumin combined with vasoconstrictors like terlipressin improves renal function and survival. In spontaneous bacterial peritonitis (SBP), albumin lowers the risk of acute kidney injury and mortality, particularly in high-risk cirrhotic patients. Post-paracentesis albumin reduces circulatory dysfunction and may enhance survival in cirrhosis. For septic shock, trials show no overall mortality benefit over crystalloids, though albumin may offer hemodynamic advantages in specific subgroups. In acute respiratory distress syndrome (ARDS), albumin improves oxygenation in hypoalbuminemic patients, without survival benefits. During major cardiac or abdominal surgery, albumin reduces fluid needs and postoperative complications, especially in hypoalbuminemic individuals. In acute brain injury, albumin’s role is controversial: it may aid recovery after cerebral hemorrhage, but can worsen outcomes in traumatic brain injury. In trauma and ECMO patients, albumin may stabilize hemodynamics and improve outcomes in selected cases. Conclusions: Inappropriate albumin use remains common, and evidence on its optimal concentration, dose, timing, and patient selection is limited. HSA is safe and beneficial in specific situations. Routine use should follow evidence-based guidelines. Future research must identify patients who are most likely to benefit and clarify optimal dosing strategies, concentrations, and therapeutic goals.

1 February 2017 in European Journal of Anaesthesiology
Verified
Journal Article
Closed access
GEGemma Echarri
Gemma Echarri
PDPaula Duque-Sosa
Paula Duque-Sosa
RCRaquel Callejas
Raquel Callejas
NGNuria Garcia-Fernandez
Nuria Garcia-Fernandez
JNJorge M. Nunez-Cordoba
Jorge M. Nunez-Cordoba
PMPablo Monedero
Pablo Monedero
Four predictive models for acute kidney injury associated with cardiac surgery were developed by Demirjian in the United States in 2012. However, the usefulness of these models in clinical practice needs to be established in different populations independent of that used to develop the models. Our aim was to evaluate the predictive performance of these models in a Spanish population. A multicentre, prospective observational study. Twenty-three Spanish hospitals in 2012 and 2013. Of 1067 consecutive cardiac patients recruited for the study, 1014 patients remained suitable for the final analysis. Dialysis therapy, and a composite outcome of either a doubling of the serum creatinine level or dialysis therapy, in the 2 weeks (or until discharge, if sooner) after cardiac surgery. Of the 1014 patients analysed, 34 (3.4%) required dialysis and 95 (9.4%) had either dialysis or doubled their serum creatinine level. The areas under the receiver operating characteristic curves of the two predictive models for dialysis therapy, which include either presurgical variables only, or combined presurgical and intrasurgical variables, were 0.79 and 0.80, respectively. The model for the composite endpoint that combined presurgical and intrasurgical variables showed better discriminatory ability than the model that included only presurgical variables: the areas under the receiver operating characteristic curves were 0.76 and 0.70, respectively. All four models lacked calibration for their respective outcomes in our Spanish population. Overall, the lack of calibration of these models and the difficulty in using the models clinically because of the large number of variables limit their applicability.

21 May 2025 in Revista Española de Anestesiología y Reanimación (English Edition)
Verified
Journal Article
Open access
ALA. Lara-Jiménez
A. Lara-Jiménez
PMP. Monedero
P. Monedero
GEGemma Echarri
Gemma Echarri
The urinary biomarker [TIMP-2]×[IGFBP7] enables the prediction of postoperative acute kidney injury (PO-AKI). Our study aimed to assess the incidence of PO-AKI in high-risk patients undergoing major abdominal surgery and to evaluate the impact of implementing KDIGO renal optimization measures in those with renal stress identified by [TIMP-2]×[IGFBP7]. This was a prospective study including 182 patients who underwent major abdominal surgery. Perioperative data, [TIMP-2]×[IGFBP7] levels, and the implementation of KDIGO renal protection strategies in the ICU were collected. Predictors of PO-AKI were identified through multivariate analysis. The overall incidence of PO-AKI was 25.3%, reaching 42.7% in ICU patients. [TIMP-2]×[IGFBP7] showed moderate predictive ability (AUROC = 0.74), with a PO-AKI incidence of 47.5% in patients with elevated levels. Despite the implementation of KDIGO measures in the ICU, the incidence of PO-AKI in patients with elevated [TIMP-2]×[IGFBP7] was 65.6%. In multivariate analysis, the main predictors of PO-AKI were elevated [TIMP-2]×[IGFBP7] (OR = 6.3; 95% CI: 2.6-15.6; p < 0.001), male sex (OR = 6.1; 95% CI: 1.9-19.6; p = 0.002), and ICU admission (OR = 4.5; 95% CI: 1.5-13.6; p = 0.009). PO-AKI is common after major abdominal surgery, particularly in ICU patients. The [TIMP-2]×[IGFBP7] biomarker allows for early identification of at-risk patients, although the implementation of KDIGO measures in the ICU did not significantly reduce its incidence.